Laplace J P, De Riberolles C, Lecompte Y, Martelli H
Ann Rech Vet. 1981;12(1):27-33.
Heterotopic cardiac allografts were performed in unrelated Large White piglets to test (i) if such a technique could be used in young (12 days) and neonates (less than five days); (ii) if tolerance to histocompatibility antigens could be induced by donor-cells injection to piglets that were immunosuppressed with heterologous antilymphocyte serum (ALS). The experimentation included two different series. The first one involved ten allografts done in early weaned (10 days), 12-day-old piglets (mean live weight 3.5 kg). They received or not ALS 2 ml per kg per day by subcutaneous route during five consecutive days after transplantation. In addition, two of the ALS treated piglets received endovenously, on day 7 after transplantation, cryoconservated cells from the spleen of the heart-donor. The second series involved ten allografts performed in suckling piglets just after birth at a mean live weight of 1.4 kg. These animals were first thymectomized at day 0 (6 h to 44 h after birth), and then received ALS (4 ml per kg by intraperitoneal route) on day 1. The heterotopic cardiac allograft was performed on day 2. Out of them, two received endovenously, on day 3, conservated splenic cells from the heart donor. In both series the heterotopic cardiac allograft was done, after right nephrectomy, anastomosing the donor thoracic aorta end to side to the recipient abdominal aorta, and the donor pulmonary artery end to side to the recipient inferior vena cava. From the surgical point of view, it appeared that the heterotopic cardiac allograft was easy to perform, and successful in most cases, in 12-day-old piglets. The same operation in neonates was as easy to perform as in older animals, but most failed to survive due to hemorragic leakage and post operative shock (repetitive anesthesia, insufficient suckling). From the immunological point of view, we failed to obtain any active enhancement of heart allograft with significant prolongation of the survival of the allogenic heart allograft (electro-cardiogram from epicardic electrodes). Rejection usually occurred in 6 to 8 days whatever the treatment (ALS with or without splenic cells from the donor, or nothing).
在不相关的大白仔猪身上进行异位心脏同种异体移植，以测试：（i）这种技术是否可用于幼龄仔猪（12日龄）和新生仔猪（小于5日龄）；（ii）通过向用异种抗淋巴细胞血清（ALS）免疫抑制的仔猪注射供体细胞，是否可诱导对组织相容性抗原的耐受性。实验包括两个不同系列。第一个系列涉及在早期断奶（10日龄）、12日龄仔猪（平均活重3.5千克）身上进行的10次同种异体移植。移植后连续5天，它们每天按每千克2毫升的剂量通过皮下途径接受或不接受ALS。此外，在移植后第7天，2只接受ALS治疗的仔猪通过静脉内途径接受了来自心脏供体脾脏的冷冻保存细胞。第二个系列涉及在出生后平均活重1.4千克的哺乳仔猪身上进行的10次同种异体移植。这些动物在出生后第0天（出生后6小时至44小时）首先进行胸腺切除术，然后在第1天通过腹腔途径接受ALS（每千克4毫升）。异位心脏同种异体移植在第2天进行。其中，2只在第3天通过静脉内途径接受了来自心脏供体的保存脾脏细胞。在两个系列中，在右肾切除术后进行异位心脏同种异体移植，将供体胸主动脉端端吻合到受体腹主动脉，将供体肺动脉端端吻合到受体下腔静脉。从手术角度来看，在12日龄仔猪中，异位心脏同种异体移植似乎易于实施，且大多数情况下是成功的。在新生仔猪中进行同样的手术与在年长动物中一样易于实施，但大多数由于出血渗漏和术后休克（反复麻醉、哺乳不足）而未能存活。从免疫学角度来看，我们未能通过显著延长同种异体心脏移植的存活时间（通过心外膜电极记录心电图）来获得对心脏同种异体移植的任何积极增强作用。无论治疗方式如何（使用或不使用来自供体的脾脏细胞的ALS，或不进行任何处理），排斥反应通常在6至8天内发生。
